Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety Study of 4th LBVH0101 After the Primary Vaccination in LG-VHCL002 Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Were vaccinated with LBVH0101 or Hiberix™ three times in LG-VHCL002 study~* Healthy male and female infants at the age of 12 to 15 months from birth~* The infants and their parents/legally acceptable representative could comply with all of the scheduled visits in the study~* The parents/legally acceptable representative signed the written consent form.~Exclusion Criteria:~* Subject had been vaccinated with 4th shot of Haemophilus influenzae type b~* Subject is scheduled to be administered with any vaccine other than those specified in the protocol as allowed according to the Standard Immunization Schedule, between the 4th vaccination and Completion Visit~* Subject had suffered from any infectious disease caused by Haemophilus influenzae type b~* Subject has fever of ≥ 37.5°C (axillary temperature) at the day of vaccination~* There is a clear or suspected immune function disorder~* Systemic corticosteroid (prednisolone or equivalent \> 0.5 mg/kg/day) was administered for more than 14 days within 30 days prior to administration of the test vaccine or any systemic immunosuppressant was used

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 15 Months
- Healthy Volunteers: f

Study Arms:
- LBVH0101 (Type: EXPERIMENTAL): None
- Hiberix (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).